Peptide-based Cancer Therapeutics Market Likely to Surpass USD 18.7 Billion by 2035

Global Peptide-based Cancer Therapeutics Market Forecast 2035:

According to the report, the global peptide-based cancer therapeutics market is projected to expand from USD 8.5 billion in 2025 to USD 18.7 billion by 2035, registering a CAGR of 8.2%, the highest during the forecast period. The peptide-based cancer therapeutics market is undergoing a solid growth due to the rising cancer rate and the need of providing more specific and personalized ways of treatment. Unlike conventional chemotherapy and radiotherapy, peptide therapeutics have a high specificity, less toxicity on the body system, and can successfully regulate biological pathways. The modern trends of peptide design, synthesis, and delivery methods such as conjugation with nanoparticles, liposomes and cell-penetrating delivery, are increasing the efficacy and stability, further driving the uptake in the market.

Immuno-oncology and combination therapies, which enhance the outcomes of the immunological response and treatment, are also used to expand the market growth of peptides. Also, the growing investment on the research and development is enhancing innovation in a variety of types of cancer, coupled with an increasing number of clinical trials in the pipeline. Although the development costs and complicated regulatory processes are a challenge, continued technological improvements, attention to individualized medicines, and incorporation with modern drug delivery system are presenting vast opportunities, which will make the continuous growth of the peptide-based cancer therapeutics market across the world a certainty.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Peptide-based Cancer Therapeutics Market”

Increasing use of peptide-based therapeutics in immuno-oncology and combination treatments is also influencing market demand with this type of peptides being able to specifically target cancer cells and also boosting immune response in the body. In combination with the chemotherapy, targeted therapy, and immune checkpoint inhibitors, peptides enhance the efficacy of treatment, cut the side effects, and provide synergistic anti-cancer effects, which makes them a desirable choice in oncology therapy of the advanced and personalized treatment.

Production of peptide-based cancer therapeutics is costly because it is a complex process with stringent quality regulations and highly developed technologies of delivery. Such costs and a rigorous preclinical and clinical testing procedures make manufacturers financially challenged. Consequently, pricing of peptide therapeutics is still high, so accessibility to the therapeutics in some markets is less, and its slow adoption is hindered, especially in cost-sensitive marketplaces.

The growing rate of clinical trials and pipeline development in peptide-based cancer therapeutics creates a lot of growth opportunities. The continued efforts in the development of peptide design, targeted delivery and combination therapies are being pushed by on-going research on various forms of cancer, such as breast, lung and hematologic malignancies. This growing pipeline increases the possibility of new approvals, increasing the treatment options and increasing the long-term growth opportunities of the market.

Expansion of Global Peptide-based Cancer Therapeutics Market

“Innovation that propel the global peptide-based cancer therapeutics market expansion”

The peptide-based cancer therapeutics market is a rapidly growing market worldwide because of the increasing incidence of cancer, increased need of targeted and personalized therapy, and increased technology in the production and delivery of peptides.
The growth in the market is also being boosted by increased use of peptides in immuno-oncology, combination therapies, and precision medicine, and significant investment by pharmaceutical and biotechnology firms in research and development.
All these aspects also favor the creation of safer, more effective, and highly specific cancer treatment options across the globe.

Regional Analysis of Global Peptide-based Cancer Therapeutics Market

North America holds a leading position in the peptide-based cancer therapeutics market due to its well-established healthcare infrastructure, high prevalence of cancer, and strong investment in research and development. The region benefits from advanced biotechnology capabilities, early adoption of innovative therapies, and supportive regulatory frameworks that facilitate clinical trials and approvals. Additionally, the presence of major pharmaceutical and biotech companies driving peptide-based drug development further strengthens North America’s dominant market position.
The Asia Pacific peptide-based cancer therapeutics market is emerging as a high-growth region due to increasing cancer prevalence, rising healthcare expenditure, and growing awareness of advanced treatment options. Expanding access to specialized oncology care, improving healthcare infrastructure, and adoption of innovative biologics and peptide-based therapies in countries like China, Japan, and India are further fueling market growth. Additionally, supportive government initiatives and rising investment in clinical research are accelerating the region’s adoption of peptide therapeutics.

Prominent players operating in the global peptide-based cancer therapeutics market are Aileron Therapeutics Inc., Amgen Inc., AstraZeneca PLC, Bachem Holding AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Ipsen Pharma, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pepticom Ltd., Pfizer Inc., PolyPeptide Group, Polyphor Ltd., Roche Holding AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zealand Pharma A/S, Other Key Players.

The global peptide-based cancer therapeutics market has been segmented as follows:

Global Peptide-based Cancer Therapeutics Market Analysis, By Peptide Type

Antimicrobial Peptides
Cell-Penetrating Peptides
- Therapeutic Peptides
- Linear Peptides
- Cyclic Peptides
Modified Peptides
Peptide Conjugates
Peptide Vaccines
Others

Global Peptide-based Cancer Therapeutics Market Analysis, By Mechanism of Action

Apoptosis Induction
Angiogenesis Inhibition
Cell Cycle Arrest
Receptor Targeting
Immune System Modulation
Enzyme Inhibition
Signal Transduction Interference
Others

Global Peptide-based Cancer Therapeutics Market Analysis, By Cancer Type

Breast Cancer
Lung Cancer
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
Prostate Cancer
Colorectal Cancer
Pancreatic Cancer
Melanoma
Leukemia
Lymphoma
Ovarian Cancer
Gastric Cancer
Others

Global Peptide-based Cancer Therapeutics Market Analysis, By Route of Administration

Intravenous
Subcutaneous
Intramuscular
Oral
Topical
Intratumoral

Global Peptide-based Cancer Therapeutics Market Analysis, By Therapeutic Approach

Monotherapy
Combination Therapy
- With Chemotherapy
- With Immunotherapy
- With Targeted Therapy
- With Radiation Therapy

Global Peptide-based Cancer Therapeutics Market Analysis, By Deployment Environment

Indoor Facilities
Outdoor Sites
Underwater Applications
Aerial Inspection
Confined Spaces
Hazardous Zones

Global Peptide-based Cancer Therapeutics Market Analysis, By Technology

Computer Vision Systems
LIDAR & Sensor Fusion
Radiation Detection Systems
Advanced Manipulation Systems
AI & ML Technologies
Others

Global Peptide-based Cancer Therapeutics Market Analysis, By Application

Inspection & Monitoring
Maintenance & Repair
Decontamination & Cleaning
Material Handling & Transportation
Emergency Response & Disaster Management
Decommissioning & Dismantling
Sample Collection & Analysis
Others

Global Peptide-based Cancer Therapeutics Market Analysis, By End-Use

Hospitals & Clinics
- Oncology Departments
  - Solid Tumor Treatment
  - Hematological Malignancies Treatment
  - Palliative Care
  - Others
- Surgical Oncology Units
- Radiation Oncology Centers
- Intensive Care Units
- Others
Cancer Research Institutes
- Drug Discovery & Development
- Biomarker Research
- Clinical Trial Conducting
- Peptide Library Screening
- Mechanism of Action Studies
- Others
Pharmaceutical & Biotechnology Companies
- Commercial Manufacturing
- Drug Formulation Development
- Quality Control & Testing
- Scale-Up Production
- Regulatory Compliance
- Others
Contract Research Organizations (CROs)
Specialty Cancer Centers
Academic & Research Organizations
Others

Global Peptide-based Cancer Therapeutics Market Analysis, By Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global Peptide-based Cancer Therapeutics Market Outlook
  - 2.1.1. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2026-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
  - 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
  - 3.4.1. Import & Export Analysis, 2025
  - 3.4.2. Top Importing Countries
  - 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
  - 3.5.1. Manufacturer
    - 3.5.1.1. Based on the component & Raw material
  - 3.5.2. Supply Chain
  - 3.5.3. End Consumer
- 3.6. Raw Material Analysis
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Rising global cancer burden increasing demand for targeted and personalized therapies.
    - 4.1.1.2. Advances in peptide engineering and drug delivery enhancing efficacy and specificity.
    - 4.1.1.3. Strong oncology R&D investments and expanding clinical pipelines for peptide therapeutics.
  - 4.1.2. Restraints
    - 4.1.2.1. High development and manufacturing costs associated with peptide synthesis and trials.
    - 4.1.2.2. Stability, bioavailability, and delivery challenges limiting broader clinical adoption.
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Ecosystem Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Peptide-based Cancer Therapeutics Market Demand
  - 4.7.1. Historical Market Size – Value (US$ Bn), 2020-2024
  - 4.7.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
    - 4.7.2.1. Y-o-Y Growth Trends
    - 4.7.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global Peptide-based Cancer Therapeutics Market Analysis, by Peptide Type
- 6.1. Key Segment Analysis
- 6.2. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, by Peptide Type, 2021-2035
  - 6.2.1. Antimicrobial Peptides
  - 6.2.2. Cell-Penetrating Peptides
    - 6.2.2.1. Therapeutic Peptides
    - 6.2.2.2. Linear Peptides
    - 6.2.2.3. Cyclic Peptides
  - 6.2.3. Modified Peptides
  - 6.2.4. Peptide Conjugates
  - 6.2.5. Peptide Vaccines
  - 6.2.6. Others
7. Global Peptide-based Cancer Therapeutics Market Analysis, by Mechanism of Action
- 7.1. Key Segment Analysis
- 7.2. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, by Mechanism of Action, 2021-2035
  - 7.2.1. Apoptosis Induction
  - 7.2.2. Angiogenesis Inhibition
  - 7.2.3. Cell Cycle Arrest
  - 7.2.4. Receptor Targeting
  - 7.2.5. Immune System Modulation
  - 7.2.6. Enzyme Inhibition
  - 7.2.7. Signal Transduction Interference
  - 7.2.8. Others
8. Global Peptide-based Cancer Therapeutics Market Analysis, by Cancer Type
- 8.1. Key Segment Analysis
- 8.2. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, by Cancer Type, 2021-2035
  - 8.2.1. Breast Cancer
  - 8.2.2. Lung Cancer
    - 8.2.2.1. Non-Small Cell Lung Cancer
    - 8.2.2.2. Small Cell Lung Cancer
  - 8.2.3. Prostate Cancer
  - 8.2.4. Colorectal Cancer
  - 8.2.5. Pancreatic Cancer
  - 8.2.6. Melanoma
  - 8.2.7. Leukemia
  - 8.2.8. Lymphoma
  - 8.2.9. Ovarian Cancer
  - 8.2.10. Gastric Cancer
  - 8.2.11. Others
9. Global Peptide-based Cancer Therapeutics Market Analysis, by Route of Administration
- 9.1. Key Segment Analysis
- 9.2. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
  - 9.2.1. Intravenous
  - 9.2.2. Subcutaneous
  - 9.2.3. Intramuscular
  - 9.2.4. Oral
  - 9.2.5. Topical
  - 9.2.6. Intratumoral
10. Global Peptide-based Cancer Therapeutics Market Analysis, by Therapeutic Approach
- 10.1. Key Segment Analysis
- 10.2. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, by Therapeutic Approach, 2021-2035
  - 10.2.1. Monotherapy
  - 10.2.2. Combination Therapy
    - 10.2.2.1. With Chemotherapy
    - 10.2.2.2. With Immunotherapy
    - 10.2.2.3. With Targeted Therapy
    - 10.2.2.4. With Radiation Therapy
11. Global Peptide-based Cancer Therapeutics Market Analysis, by End-Use
- 11.1. Key Segment Analysis
- 11.2. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, by End-Use, 2021-2035
  - 11.2.1. Hospitals & Clinics
    - 11.2.1.1. Oncology Departments
    - 11.2.1.2. Solid Tumor Treatment
    - 11.2.1.3. Hematological Malignancies Treatment
    - 11.2.1.4. Palliative Care
    - 11.2.1.5. Others
    - 11.2.1.6. Surgical Oncology Units
    - 11.2.1.7. Radiation Oncology Centers
    - 11.2.1.8. Intensive Care Units
    - 11.2.1.9. Others
  - 11.2.2. Cancer Research Institutes
    - 11.2.2.1. Drug Discovery & Development
    - 11.2.2.2. Biomarker Research
    - 11.2.2.3. Clinical Trial Conducting
    - 11.2.2.4. Peptide Library Screening
    - 11.2.2.5. Mechanism of Action Studies
    - 11.2.2.6. Others
  - 11.2.3. Pharmaceutical & Biotechnology Companies
    - 11.2.3.1. Commercial Manufacturing
    - 11.2.3.2. Drug Formulation Development
    - 11.2.3.3. Quality Control & Testing
    - 11.2.3.4. Scale-Up Production
    - 11.2.3.5. Regulatory Compliance
    - 11.2.3.6. Others
  - 11.2.4. Contract Research Organizations (CROs)
  - 11.2.5. Specialty Cancer Centers
  - 11.2.6. Academic & Research Organizations
  - 11.2.7. Others
12. Global Peptide-based Cancer Therapeutics Market Analysis and Forecasts, by Region
- 12.1. Key Findings
- 12.2. Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
  - 12.2.1. North America
  - 12.2.2. Europe
  - 12.2.3. Asia Pacific
  - 12.2.4. Middle East
  - 12.2.5. Africa
  - 12.2.6. South America
13. North America Peptide-based Cancer Therapeutics Market Analysis
- 13.1. Key Segment Analysis
- 13.2. Regional Snapshot
- 13.3. North America Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
  - 13.3.1. Peptide Type
  - 13.3.2. Mechanism of Action
  - 13.3.3. Cancer Type
  - 13.3.4. Route of Administration
  - 13.3.5. Therapeutic Approach
  - 13.3.6. End-Use
  - 13.3.7. Country
    - 13.3.7.1. USA
    - 13.3.7.2. Canada
    - 13.3.7.3. Mexico
- 13.4. USA Peptide-based Cancer Therapeutics Market
  - 13.4.1. Country Segmental Analysis
  - 13.4.2. Peptide Type
  - 13.4.3. Mechanism of Action
  - 13.4.4. Cancer Type
  - 13.4.5. Route of Administration
  - 13.4.6. Therapeutic Approach
  - 13.4.7. End-Use
- 13.5. Canada Peptide-based Cancer Therapeutics Market
  - 13.5.1. Country Segmental Analysis
  - 13.5.2. Peptide Type
  - 13.5.3. Mechanism of Action
  - 13.5.4. Cancer Type
  - 13.5.5. Route of Administration
  - 13.5.6. Therapeutic Approach
  - 13.5.7. End-Use
- 13.6. Mexico Peptide-based Cancer Therapeutics Market
  - 13.6.1. Country Segmental Analysis
  - 13.6.2. Peptide Type
  - 13.6.3. Mechanism of Action
  - 13.6.4. Cancer Type
  - 13.6.5. Route of Administration
  - 13.6.6. Therapeutic Approach
  - 13.6.7. End-Use
14. Europe Peptide-based Cancer Therapeutics Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. Europe Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
  - 14.3.1. Peptide Type
  - 14.3.2. Mechanism of Action
  - 14.3.3. Cancer Type
  - 14.3.4. Route of Administration
  - 14.3.5. Therapeutic Approach
  - 14.3.6. End-Use
  - 14.3.7. Country
    - 14.3.7.1. Germany
    - 14.3.7.2. United Kingdom
    - 14.3.7.3. France
    - 14.3.7.4. Italy
    - 14.3.7.5. Spain
    - 14.3.7.6. Netherlands
    - 14.3.7.7. Nordic Countries
    - 14.3.7.8. Poland
    - 14.3.7.9. Russia & CIS
    - 14.3.7.10. Rest of Europe
- 14.4. Germany Peptide-based Cancer Therapeutics Market
  - 14.4.1. Country Segmental Analysis
  - 14.4.2. Peptide Type
  - 14.4.3. Mechanism of Action
  - 14.4.4. Cancer Type
  - 14.4.5. Route of Administration
  - 14.4.6. Therapeutic Approach
  - 14.4.7. End-Use
- 14.5. United Kingdom Peptide-based Cancer Therapeutics Market
  - 14.5.1. Country Segmental Analysis
  - 14.5.2. Peptide Type
  - 14.5.3. Mechanism of Action
  - 14.5.4. Cancer Type
  - 14.5.5. Route of Administration
  - 14.5.6. Therapeutic Approach
  - 14.5.7. End-Use
- 14.6. France Peptide-based Cancer Therapeutics Market
  - 14.6.1. Country Segmental Analysis
  - 14.6.2. Peptide Type
  - 14.6.3. Mechanism of Action
  - 14.6.4. Cancer Type
  - 14.6.5. Route of Administration
  - 14.6.6. Therapeutic Approach
  - 14.6.7. End-Use
- 14.7. Italy Peptide-based Cancer Therapeutics Market
  - 14.7.1. Country Segmental Analysis
  - 14.7.2. Peptide Type
  - 14.7.3. Mechanism of Action
  - 14.7.4. Cancer Type
  - 14.7.5. Route of Administration
  - 14.7.6. Therapeutic Approach
  - 14.7.7. End-Use
- 14.8. Spain Peptide-based Cancer Therapeutics Market
  - 14.8.1. Country Segmental Analysis
  - 14.8.2. Peptide Type
  - 14.8.3. Mechanism of Action
  - 14.8.4. Cancer Type
  - 14.8.5. Route of Administration
  - 14.8.6. Therapeutic Approach
  - 14.8.7. End-Use
- 14.9. Netherlands Peptide-based Cancer Therapeutics Market
  - 14.9.1. Country Segmental Analysis
  - 14.9.2. Peptide Type
  - 14.9.3. Mechanism of Action
  - 14.9.4. Cancer Type
  - 14.9.5. Route of Administration
  - 14.9.6. Therapeutic Approach
  - 14.9.7. End-Use
- 14.10. Nordic Countries Peptide-based Cancer Therapeutics Market
  - 14.10.1. Country Segmental Analysis
  - 14.10.2. Peptide Type
  - 14.10.3. Mechanism of Action
  - 14.10.4. Cancer Type
  - 14.10.5. Route of Administration
  - 14.10.6. Therapeutic Approach
  - 14.10.7. End-Use
- 14.11. Poland Peptide-based Cancer Therapeutics Market
  - 14.11.1. Country Segmental Analysis
  - 14.11.2. Peptide Type
  - 14.11.3. Mechanism of Action
  - 14.11.4. Cancer Type
  - 14.11.5. Route of Administration
  - 14.11.6. Therapeutic Approach
  - 14.11.7. End-Use
- 14.12. Russia & CIS Peptide-based Cancer Therapeutics Market
  - 14.12.1. Country Segmental Analysis
  - 14.12.2. Peptide Type
  - 14.12.3. Mechanism of Action
  - 14.12.4. Cancer Type
  - 14.12.5. Route of Administration
  - 14.12.6. Therapeutic Approach
  - 14.12.7. End-Use
- 14.13. Rest of Europe Peptide-based Cancer Therapeutics Market
  - 14.13.1. Country Segmental Analysis
  - 14.13.2. Peptide Type
  - 14.13.3. Mechanism of Action
  - 14.13.4. Cancer Type
  - 14.13.5. Route of Administration
  - 14.13.6. Therapeutic Approach
  - 14.13.7. End-Use
15. Asia Pacific Peptide-based Cancer Therapeutics Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Asia Pacific Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
  - 15.3.1. Peptide Type
  - 15.3.2. Mechanism of Action
  - 15.3.3. Cancer Type
  - 15.3.4. Route of Administration
  - 15.3.5. Therapeutic Approach
  - 15.3.6. End-Use
  - 15.3.7. Country
    - 15.3.7.1. China
    - 15.3.7.2. India
    - 15.3.7.3. Japan
    - 15.3.7.4. South Korea
    - 15.3.7.5. Australia and New Zealand
    - 15.3.7.6. Indonesia
    - 15.3.7.7. Malaysia
    - 15.3.7.8. Thailand
    - 15.3.7.9. Vietnam
    - 15.3.7.10. Rest of Asia Pacific
- 15.4. China Peptide-based Cancer Therapeutics Market
  - 15.4.1. Country Segmental Analysis
  - 15.4.2. Peptide Type
  - 15.4.3. Mechanism of Action
  - 15.4.4. Cancer Type
  - 15.4.5. Route of Administration
  - 15.4.6. Therapeutic Approach
  - 15.4.7. End-Use
- 15.5. India Peptide-based Cancer Therapeutics Market
  - 15.5.1. Country Segmental Analysis
  - 15.5.2. Peptide Type
  - 15.5.3. Mechanism of Action
  - 15.5.4. Cancer Type
  - 15.5.5. Route of Administration
  - 15.5.6. Therapeutic Approach
  - 15.5.7. End-Use
- 15.6. Japan Peptide-based Cancer Therapeutics Market
  - 15.6.1. Country Segmental Analysis
  - 15.6.2. Peptide Type
  - 15.6.3. Mechanism of Action
  - 15.6.4. Cancer Type
  - 15.6.5. Route of Administration
  - 15.6.6. Therapeutic Approach
  - 15.6.7. End-Use
- 15.7. South Korea Peptide-based Cancer Therapeutics Market
  - 15.7.1. Country Segmental Analysis
  - 15.7.2. Peptide Type
  - 15.7.3. Mechanism of Action
  - 15.7.4. Cancer Type
  - 15.7.5. Route of Administration
  - 15.7.6. Therapeutic Approach
  - 15.7.7. End-Use
- 15.8. Australia and New Zealand Peptide-based Cancer Therapeutics Market
  - 15.8.1. Country Segmental Analysis
  - 15.8.2. Peptide Type
  - 15.8.3. Mechanism of Action
  - 15.8.4. Cancer Type
  - 15.8.5. Route of Administration
  - 15.8.6. Therapeutic Approach
  - 15.8.7. End-Use
- 15.9. Indonesia Peptide-based Cancer Therapeutics Market
  - 15.9.1. Country Segmental Analysis
  - 15.9.2. Peptide Type
  - 15.9.3. Mechanism of Action
  - 15.9.4. Cancer Type
  - 15.9.5. Route of Administration
  - 15.9.6. Therapeutic Approach
  - 15.9.7. End-Use
- 15.10. Malaysia Peptide-based Cancer Therapeutics Market
  - 15.10.1. Country Segmental Analysis
  - 15.10.2. Peptide Type
  - 15.10.3. Mechanism of Action
  - 15.10.4. Cancer Type
  - 15.10.5. Route of Administration
  - 15.10.6. Therapeutic Approach
  - 15.10.7. End-Use
- 15.11. Thailand Peptide-based Cancer Therapeutics Market
  - 15.11.1. Country Segmental Analysis
  - 15.11.2. Peptide Type
  - 15.11.3. Mechanism of Action
  - 15.11.4. Cancer Type
  - 15.11.5. Route of Administration
  - 15.11.6. Therapeutic Approach
  - 15.11.7. End-Use
- 15.12. Vietnam Peptide-based Cancer Therapeutics Market
  - 15.12.1. Country Segmental Analysis
  - 15.12.2. Peptide Type
  - 15.12.3. Mechanism of Action
  - 15.12.4. Cancer Type
  - 15.12.5. Route of Administration
  - 15.12.6. Therapeutic Approach
  - 15.12.7. End-Use
- 15.13. Rest of Asia Pacific Peptide-based Cancer Therapeutics Market
  - 15.13.1. Country Segmental Analysis
  - 15.13.2. Peptide Type
  - 15.13.3. Mechanism of Action
  - 15.13.4. Cancer Type
  - 15.13.5. Route of Administration
  - 15.13.6. Therapeutic Approach
  - 15.13.7. End-Use
16. Middle East Peptide-based Cancer Therapeutics Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Middle East Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Peptide Type
  - 16.3.2. Mechanism of Action
  - 16.3.3. Cancer Type
  - 16.3.4. Route of Administration
  - 16.3.5. Therapeutic Approach
  - 16.3.6. End-Use
  - 16.3.7. Country
    - 16.3.7.1. Turkey
    - 16.3.7.2. UAE
    - 16.3.7.3. Saudi Arabia
    - 16.3.7.4. Israel
    - 16.3.7.5. Rest of Middle East
- 16.4. Turkey Peptide-based Cancer Therapeutics Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Peptide Type
  - 16.4.3. Mechanism of Action
  - 16.4.4. Cancer Type
  - 16.4.5. Route of Administration
  - 16.4.6. Therapeutic Approach
  - 16.4.7. End-Use
- 16.5. UAE Peptide-based Cancer Therapeutics Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Peptide Type
  - 16.5.3. Mechanism of Action
  - 16.5.4. Cancer Type
  - 16.5.5. Route of Administration
  - 16.5.6. Therapeutic Approach
  - 16.5.7. End-Use
- 16.6. Saudi Arabia Peptide-based Cancer Therapeutics Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Peptide Type
  - 16.6.3. Mechanism of Action
  - 16.6.4. Cancer Type
  - 16.6.5. Route of Administration
  - 16.6.6. Therapeutic Approach
  - 16.6.7. End-Use
- 16.7. Israel Peptide-based Cancer Therapeutics Market
  - 16.7.1. Country Segmental Analysis
  - 16.7.2. Peptide Type
  - 16.7.3. Mechanism of Action
  - 16.7.4. Cancer Type
  - 16.7.5. Route of Administration
  - 16.7.6. Therapeutic Approach
  - 16.7.7. End-Use
- 16.8. Rest of Middle East Peptide-based Cancer Therapeutics Market
  - 16.8.1. Country Segmental Analysis
  - 16.8.2. Peptide Type
  - 16.8.3. Mechanism of Action
  - 16.8.4. Cancer Type
  - 16.8.5. Route of Administration
  - 16.8.6. Therapeutic Approach
  - 16.8.7. End-Use
17. Africa Peptide-based Cancer Therapeutics Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Africa Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Peptide Type
  - 17.3.2. Mechanism of Action
  - 17.3.3. Cancer Type
  - 17.3.4. Route of Administration
  - 17.3.5. Therapeutic Approach
  - 17.3.6. End-Use
  - 17.3.7. Country
    - 17.3.7.1. South Africa
    - 17.3.7.2. Egypt
    - 17.3.7.3. Nigeria
    - 17.3.7.4. Algeria
    - 17.3.7.5. Rest of Africa
- 17.4. South Africa Peptide-based Cancer Therapeutics Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Peptide Type
  - 17.4.3. Mechanism of Action
  - 17.4.4. Cancer Type
  - 17.4.5. Route of Administration
  - 17.4.6. Therapeutic Approach
  - 17.4.7. End-Use
- 17.5. Egypt Peptide-based Cancer Therapeutics Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Peptide Type
  - 17.5.3. Mechanism of Action
  - 17.5.4. Cancer Type
  - 17.5.5. Route of Administration
  - 17.5.6. Therapeutic Approach
  - 17.5.7. End-Use
- 17.6. Nigeria Peptide-based Cancer Therapeutics Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Peptide Type
  - 17.6.3. Mechanism of Action
  - 17.6.4. Cancer Type
  - 17.6.5. Route of Administration
  - 17.6.6. Therapeutic Approach
  - 17.6.7. End-Use
- 17.7. Algeria Peptide-based Cancer Therapeutics Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Peptide Type
  - 17.7.3. Mechanism of Action
  - 17.7.4. Cancer Type
  - 17.7.5. Route of Administration
  - 17.7.6. Therapeutic Approach
  - 17.7.7. End-Use
- 17.8. Rest of Africa Peptide-based Cancer Therapeutics Market
  - 17.8.1. Country Segmental Analysis
  - 17.8.2. Peptide Type
  - 17.8.3. Mechanism of Action
  - 17.8.4. Cancer Type
  - 17.8.5. Route of Administration
  - 17.8.6. Therapeutic Approach
  - 17.8.7. End-Use
18. South America Peptide-based Cancer Therapeutics Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. South America Peptide-based Cancer Therapeutics Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Peptide Type
  - 18.3.2. Mechanism of Action
  - 18.3.3. Cancer Type
  - 18.3.4. Route of Administration
  - 18.3.5. Therapeutic Approach
  - 18.3.6. End-Use
  - 18.3.7. Country
    - 18.3.7.1. Brazil
    - 18.3.7.2. Argentina
    - 18.3.7.3. Rest of South America
- 18.4. Brazil Peptide-based Cancer Therapeutics Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Peptide Type
  - 18.4.3. Mechanism of Action
  - 18.4.4. Cancer Type
  - 18.4.5. Route of Administration
  - 18.4.6. Therapeutic Approach
  - 18.4.7. End-Use
- 18.5. Argentina Peptide-based Cancer Therapeutics Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Peptide Type
  - 18.5.3. Mechanism of Action
  - 18.5.4. Cancer Type
  - 18.5.5. Route of Administration
  - 18.5.6. Therapeutic Approach
  - 18.5.7. End-Use
- 18.6. Rest of South America Peptide-based Cancer Therapeutics Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Peptide Type
  - 18.6.3. Mechanism of Action
  - 18.6.4. Cancer Type
  - 18.6.5. Route of Administration
  - 18.6.6. Therapeutic Approach
  - 18.6.7. End-Use
19. Key Players/ Company Profile
- 19.1. Aileron Therapeutics Inc.
  - 19.1.1. Company Details/ Overview
  - 19.1.2. Company Financials
  - 19.1.3. Key Customers and Competitors
  - 19.1.4. Business/ Industry Portfolio
  - 19.1.5. Product Portfolio/ Specification Details
  - 19.1.6. Pricing Data
  - 19.1.7. Strategic Overview
  - 19.1.8. Recent Developments
- 19.2. Amgen Inc.
- 19.3. AstraZeneca PLC
- 19.4. Bachem Holding AG
- 19.5. Bristol-Myers Squibb Company
- 19.6. Eli Lilly and Company
- 19.7. GlaxoSmithKline plc
- 19.8. Ipsen Pharma
- 19.9. Johnson & Johnson
- 19.10. Merck & Co. Inc.
- 19.11. Novartis AG
- 19.12. Pepticom Ltd.
- 19.13. Pfizer Inc.
- 19.14. PolyPeptide Group
- 19.15. Polyphor Ltd.
- 19.16. Roche Holding AG
- 19.17. Sanofi SA
- 19.18. Takeda Pharmaceutical Company Limited
- 19.19. Teva Pharmaceutical Industries Ltd.
- 19.20. Zealand Pharma A/S
- 19.21. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation